|Bid||141.66 x 100|
|Ask||141.67 x 400|
|Day's Range||140.93 - 142.86|
|52 Week Range||121.48 - 150.28|
|PE Ratio (TTM)||12.45|
|Dividend & Yield||2.84 (1.98%)|
|1y Target Est||N/A|
Chubb Limited's (CB) growth prospects scale on strategic initiatives and a continued focus to enhance shareholders' value.
Eli Lilly • LLY-NYSE Long-Term Buy • Price $82.17 on Sept. 12 by Hilliard Lyons At the European Society for Medical Oncology Annual Congress, Lilly presented strong data from a key trial on its cancer drug Abemaciclib. As a reminder to investors, while cross-trial comparisons are difficult to make, the presentation provided physicians and investors the best opportunity to compare Abemaciclib to the other CDK4/6 inhibitors, and we think it can take some market share from competitors in this niche.
Chubb's one-year forward PE ratio stands at 13.15x, compared with the peer average of 12.09x, which means that Chubb is trading at a premium valuation.